{"id":"https://openalex.org/W282925303","doi":"https://doi.org/10.1097/01.fbp.0000091471.79060.ed","title":"Substitution for PCP, disruption of prepulse inhibition and hyperactivity induced by N-methyl-D-aspartate receptor antagonists: preferential involvement of the NR2B rather than NR2A subunit.","display_name":"Substitution for PCP, disruption of prepulse inhibition and hyperactivity induced by N-methyl-D-aspartate receptor antagonists: preferential involvement of the NR2B rather than NR2A subunit.","publication_year":2003,"publication_date":"2003-09-01","ids":{"openalex":"https://openalex.org/W282925303","doi":"https://doi.org/10.1097/01.fbp.0000091471.79060.ed","mag":"282925303","pmid":"https://pubmed.ncbi.nlm.nih.gov/14501261"},"language":"en","primary_location":{"id":"pmid:14501261","doi":"https://doi.org/10.1097/01.fbp.0000091471.79060.ed","is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/14501261","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Behavioural pharmacology","raw_type":"Journal Article"},"volume":null,"type":"article","indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5013346333","display_name":"Fr\u00e9d\u00e9rique Chaperon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"F Chaperon","raw_affiliation_strings":["Novartis Pharma AG, Nervous System Research, Basel, Switzerland. frederique.chaperon@pharma.novartis.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharma AG, Nervous System Research, Basel, Switzerland. frederique.chaperon@pharma.novartis.com","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":null,"display_name":"W M\u00fcller","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W M\u00fcller","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022765017","display_name":"Yves P. Auberson","orcid":"https://orcid.org/0000-0001-5800-4811","observed_orcids":["https://orcid.org/0000-0001-5800-4811"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Y P Auberson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067902930","display_name":"Mark David Tricklebank","orcid":"https://orcid.org/0000-0002-9949-6290","observed_orcids":["https://orcid.org/0000-0002-9949-6290"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M D Tricklebank","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5113871291","display_name":"Hans C. Neijt","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H C Neijt","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.8076,"has_fulltext":false,"cited_by_count":51,"citation_normalized_percentile":{"value":0.62529506,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"14","issue":"5-6","first_page":"477","last_page":"87"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.5224999785423279,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.5224999785423279,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.3788999915122986,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.04410000145435333,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/phencyclidine","display_name":"phencyclidine","score":0.9800000190734863},{"id":"https://openalex.org/keywords/nmda-receptor-antagonist","display_name":"NMDA receptor antagonists","score":0.8730000257492065},{"id":"https://openalex.org/keywords/discriminative-stimuli","display_name":"discriminative stimulus","score":0.8230000138282776},{"id":"https://openalex.org/keywords/nr2b-subunit","display_name":"NR2B subunit","score":0.8240000009536743},{"id":"https://openalex.org/keywords/nr2a-subunit","display_name":"NR2A subunit","score":0.9559999704360962},{"id":"https://openalex.org/keywords/ro-25-6981","display_name":"Ro 25-6981","score":0.8709999918937683},{"id":"https://openalex.org/keywords/nvp-aam077","display_name":"NVP-AAM077","score":0.9520000219345093},{"id":"https://openalex.org/keywords/mk-801","display_name":"MK-801","score":0.8259999752044678},{"id":"https://openalex.org/keywords/prepulse-inhibition","display_name":"prepulse inhibition","score":0.9340000152587891},{"id":"https://openalex.org/keywords/startle-response","display_name":"startle response","score":0.9750000238418579},{"id":"https://openalex.org/keywords/locomotor-hyperactivity","display_name":"locomotor hyperactivity","score":0.9229999780654907},{"id":"https://openalex.org/keywords/locomotor-inhibition","display_name":"locomotor inhibition","score":0.34599998593330383},{"id":"https://openalex.org/keywords/enantiomers","display_name":"enantiomers","score":0.4869999885559082}],"concepts":[{"id":"https://openalex.org/C67018056","wikidata":"https://www.wikidata.org/wiki/Q414896","display_name":"NMDA receptor","level":3,"score":0.8688318133354187},{"id":"https://openalex.org/C2778851735","wikidata":"https://www.wikidata.org/wiki/Q407324","display_name":"Phencyclidine","level":4,"score":0.8381786346435547},{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.7192517518997192},{"id":"https://openalex.org/C42533223","wikidata":"https://www.wikidata.org/wiki/Q1378064","display_name":"ED50","level":3,"score":0.6701840758323669},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6498555541038513},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.637844979763031},{"id":"https://openalex.org/C86811712","wikidata":"https://www.wikidata.org/wiki/Q410943","display_name":"Competitive antagonist","level":4,"score":0.6196539998054504},{"id":"https://openalex.org/C141421786","wikidata":"https://www.wikidata.org/wiki/Q1128897","display_name":"Prepulse inhibition","level":3,"score":0.5929200649261475},{"id":"https://openalex.org/C2777836312","wikidata":"https://www.wikidata.org/wiki/Q4386371","display_name":"Dizocilpine","level":4,"score":0.4826579689979553},{"id":"https://openalex.org/C2778122271","wikidata":"https://www.wikidata.org/wiki/Q410943","display_name":"Receptor antagonist","level":4,"score":0.42764905095100403},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.3579663634300232},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.18052417039871216},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.11058145761489868},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.0},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003216","descriptor_name":"Conditioning, Operant","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004193","descriptor_name":"Discrimination Learning","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D006213","descriptor_name":"Hallucinogens","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D008124","descriptor_name":"Locomotion","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010622","descriptor_name":"Phencyclidine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D016194","descriptor_name":"Receptors, N-Methyl-D-Aspartate","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D017208","descriptor_name":"Rats, Wistar","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018691","descriptor_name":"Excitatory Amino Acid Antagonists","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:14501261","doi":"https://doi.org/10.1097/01.fbp.0000091471.79060.ed","is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/14501261","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Behavioural pharmacology","raw_type":"Journal Article"},{"id":"mag:282925303","doi":"https://doi.org/10.1097/01.fbp.0000091471.79060.ed","is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/14501261","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9074000120162964,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2092827669","https://openalex.org/W2001721703","https://openalex.org/W2078358186","https://openalex.org/W2157160837","https://openalex.org/W2091052589","https://openalex.org/W1966423911","https://openalex.org/W2320341697","https://openalex.org/W2094780612","https://openalex.org/W2033011495","https://openalex.org/W2058086587"],"abstract_inverted_index":{"The":[0,16,54,119,187],"non-competitive":[1],"NMDA":[2,27,55,65,105,123,152,191,260,288,300],"receptor":[3,28,66,192,261],"antagonist":[4,67,121,154],"phencyclidine":[5],"(PCP)":[6],"is":[7,30],"known":[8],"to":[9,24,40,160,194,205,293],"produce":[10,161],"a":[11,49,135,272,296],"discriminative":[12,163,278],"stimulus":[13],"in":[14,32,48,134,183,275],"rats.":[15],"first":[17],"aim":[18],"of":[19,35,75,100,114,122,141,180,189,200,298],"the":[20,63,126,150,178,181,196,201,259,263,267,276],"present":[21],"study":[22],"was":[23,209],"investigate":[25],"which":[26],"subtype(s)":[29],"involved":[31],"this":[33,184],"effect":[34],"PCP.":[36],"Rats":[37],"were":[38],"trained":[39],"discriminate":[41],"PCP":[42,145,212],"(2":[43],"mg/kg;":[44,60,71,110,131,157,214,219,224,230,244],"i.p.)":[45,61,72,132,158,225,231,245],"from":[46,295],"saline":[47],"two":[50],"lever":[51],"operant":[52,185],"task.":[53,186],"channel":[56],"blocker,":[57],"(+)MK-801":[58],"(0.1":[59],"and":[62,79,91,173,204,226,234,250],"competitive":[64,104],"SDZ":[68,92,107,168,174,216,221],"220-581":[69,169,217],"(3":[70],"produced":[73,238],"76%":[74],"PCP-lever":[76,115,142],"selection":[77],"(ED50=0.045":[78],"2":[80],"mg/kg,":[81],"respectively),":[82],"whereas":[83],"their":[84],"respective":[85],"inactive":[86],"enantiomers":[87],"(-)MK-801":[88],"(0.025-0.1":[89],"mg/kg)":[90,95],"221-653":[93],"(2-5":[94],"induced":[96,112],"less":[97],"than":[98,139,266],"30%":[99],"PCP-appropriate":[101],"responding.":[102],"Another":[103],"antagonist,":[106],"EAB-515":[108,175,222],"(30":[109],"i.p.),":[111],"63%":[113],"responding":[116],"(ED50=23.48":[117],"mg/kg).":[118,147],"selective":[120],"receptors":[124],"containing":[125,262],"NR1A/NR2B-subunits":[127],"Ro":[128,227],"25-6981":[129,228],"(20":[130],"resulted":[133],"complete":[136],"substitution":[137],"(more":[138],"80%":[140],"selection)":[143],"for":[144],"(ED50=8.59":[146],"In":[148,240,254,280],"contrast,":[149,241],"NR1A/NR2A":[151],"receptor-preferring":[153],"NVP-AAM077":[155,171,242],"(2-10":[156],"failed":[159],"PCP-like":[162,277],"stimuli.":[164],"At":[165],"high":[166,236],"doses":[167,237],"(ED50=2.44),":[170],"(ED50=8.33)":[172],"(ED50=25.81)":[176],"decreased":[177],"performance":[179],"rats":[182],"ability":[188],"these":[190],"antagonists":[193,289],"disrupt":[195,248],"prepulse":[197],"inhibition":[198],"(PPI)":[199],"startle":[202],"response":[203],"alter":[206],"locomotor":[207,252],"activity":[208],"also":[210],"studied.":[211],"(0.5-2":[213],"s.c.),":[215,220],"(0.5-5":[218],"(1-30":[223],"(5-20":[229,243],"disrupted":[232],"PPI":[233,249],"at":[235],"hyperlocomotion.":[239],"did":[246],"not":[247,291],"reduced":[251],"activity.":[253],"conclusion,":[255],"it":[256],"appears":[257],"that":[258],"NR2B,":[264],"rather":[265],"NR2A":[268],"subunit,":[269],"may":[270],"play":[271],"major":[273],"role":[274],"stimulus.":[279],"addition,":[281],"sensory":[282],"motor":[283],"gating":[284],"disturbances":[285],"associated":[286],"with":[287],"do":[290],"seem":[292],"result":[294],"blockade":[297],"NR1/NR2A-containing":[299],"receptors.":[301]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":4},{"year":2012,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}